Rho-kinase inhibition attenuates airway responsiveness, inflammation, matrix remodeling, and oxidative stress activation induced by chronic inflammation

Samantha Souza Possa,1 Homar Toledo Charafeddine,1 Renato Fraga Righetti,1 Patricia Angeli da Silva,1 Rafael Almeida-Reis,1 Beatriz Manguere Saraiva-Romanholo,1 Adenir Perini,1 Carla Máximo Prado,2 Edna Aparecida Leick-Maldonado,1 Milton A. Martins,1 and Iolandj da Fátima Lopes Calvo Tíbério1

1Department of Medicine, School of Medicine, University of São Paulo, and 2Department of Biological Science, Federal University of São Paulo, Diadema, São Paulo, Brazil

Submitted 30 January 2012; accepted in final form 19 September 2012

Asthma is an inflammatory pulmonary disease characterized by airway hyperresponsiveness and inflammation, which may be increased by inflammatory mediators, neurotransmitters and inhaled contractile stimuli such as allergens and irritant air pollutants (8). These processes lead to cellular and structural changes in the airways, known as airway remodeling (24, 32, 47).

The most important medications for the control of asthma are the inhaled corticosteroids. However, these drugs present several deficiencies, including heterogeneous individual patient responses and the presence of steroid-resistant processes in airflow inflammation (8). Furthermore, the corticosteroids are ineffective in reversing airway remodeling and its functional consequences, including a large effect on airway hyperresponsiveness (7). In this context, there is a growing need for new alternative therapeutic agents that better regulate the various processes involved in the pathophysiology of asthma.

Y-27632 [(+)-(R)-trans-4-(1-aminooethyl)-N-(4-pyrydil) cyclohexanecarboxamide monohydrate] is an investigational new drug for the treatment for asthma. Y-27632 is a highly selective inhibitor of the Rho-kinase pathway that reverses G protein sensitization and consequently relaxes the airway smooth muscle (17, 45).

Ca2+ sensitization, also observed in the airways, is the increase in smooth muscle tension and/or phosphorylation of the 20-kDa regulatory light chain of myosin (MLC20) at a constant Ca2+ concentration (51). This Ca2+ sensitization is mediated in a variety of smooth muscles by a small G protein, RhoAp21, and its target protein, Rho-kinase (45), which is especially important during the sustained phase of contraction in smooth muscle (51).

Several studies have shown that the use of Rho-kinase inhibitors may be beneficial for the treatment of airway diseases. Experimentally, Rho-kinase appears to be involved in processes such as modulating the degree (and perhaps the development) of airway hyperresponsiveness (15, 38, 40), the infiltration of inflammatory cells into the airways (38, 43), and the growth factor-dependent contraction of human airway smooth muscle (9). These beneficial effects suggest that the inhibition of Rho-kinase signaling may represent a new strategy for resolving airflow limitations in asthma (51).

The aim of the present study was to evaluate the impact of the use of repeated treatment with inhaled Y-27632 on airway hyperresponsiveness, oxidative stress activation, airway extracellular matrix remodeling, eosinophilic inflammation, and T helper (Th2) and Th1 cytokine expression in an animal model of chronic airway inflammation.
MATERIALS AND METHODS

Animals. We selected 3-wk-old, pathogen-free male Hartley guinea pigs (GP) with initial weights of 300–350 g as subjects for this study. The animals received humane care in compliance with National Institutes of Health guidelines for care and use of laboratory animals. All protocols and procedures described in this study were approved by the Institutional Review Board of The University of São Paulo (São Paulo, SP, Brazil).

Experimental groups. The experimental protocol included four groups (n = 8 for each group): 1) SAL, subjected to the inhalation of aerosolized normal saline; 2) OVA, exposed to the ovalbumin solution challenge; 3) SAL-RHO, subjected to the inhalation of aerosolized normal saline and aerosolized Y-27632, starting with the fifth inhalation of saline; and 4) OVA-RHO, exposed to the ovalbumin solution challenge and aerosolized Y-27632, starting with the fifth inhalation of ovalbumin.

Induction of chronic allergic pulmonary inflammation. The induction of chronic airway inflammation was conducted as described previously (3, 23, 29, 30, 35, 44). In short, the animals were individually placed in a Plexiglas box (30 cm × 15 cm × 20 cm) coupled to an ultrasonic nebulizer (Soniclean, São Paulo, Brazil). An aerosol of ovalbumin solution (Sigma Chemical, St. Louis, MO) diluted in a sterile 0.9% NaCl solution (saline) was generated for 15 min or until respiratory distress occurred. The time that the GP were in contact with the aerosol was termed “inhalation time”. A protocol of seven inhalations was conducted twice a week over a period of 4 wk, with increasing concentrations of ovalbumin (1–5 mg/ml) to avoid the development of tolerance. In the first 2 wk (challenges 1–4), the dose of ovalbumin used was 1.0 mg/ml. In the third week (the 5th and 6th challenges), the animals received a solution containing 2.5 mg/ml of ovalbumin. In the last week of the protocol (the 7th challenge), the dose was increased to 5.0 mg/ml of ovalbumin. The control animals (the SAL group) were subjected to the same protocol with aerosolized saline; see Fig. 1 (44).

Y-27632 treatment. Starting on the fifth inhalation of the experimental protocol, the GP were exposed to 2 min of inhalation with 1 mM Y-27632 (Tocris Bioscience, Ellisville, MO) 10 min before each challenge with ovalbumin or normal saline inhalation. This protocol was based on a previous report stating that 2-min inhalation of 1 mM Y-27632 was capable of inhibiting an acetylcholine-induced increase in lung resistance without altering mean blood pressure (17). The authors administered acetylcholine 10 min after the inhalation of Y-27632 and verified that, 1 h after the inhalation of the drug, its effect on lung resistance was already present. We did not use Y-27632 by intravenous injection at a higher concentration because Uehata et al. (45) reported that this protocol can decrease mean blood pressure in hypertensive rats. In our study, on the day of the mechanical evaluation, Y-27632 inhalation was performed 1 h before the start of the experiment. We elected to administer the drug via inhalation due to its direct effect on the respiratory system and to minimize systemic effects.

Measurement of ENO. Seventy-two hours after the seventh protocol inhalation and 1 h after the Y-27632 aerosolization, the GP were anesthetized with pentobarbital sodium (50 mg/kg, intraperitoneal injection), tracheostomized, and mechanically ventilated at 60 breaths/min with a tidal volume of 8 ml/kg using a Harvard 683 ventilator (Harvard Apparatus, Boston, MA). Next, the exhaled nitric oxide (ENO) concentration was measured as described previously (23, 30). In brief, to obtain the ENO, after each animal was stabilized on the ventilator, a collection bag was attached to the expiratory output of the ventilator for 3 min. The ENO was measured using a chemiluminescence technique with a fast-responding analyzer (NOA 280; Sievers Instruments, Boulder, CO). Before each measurement, the analyzer was calibrated with an NO source certified at 47 parts per billion (ppb) (White Martins, São Paulo, Brazil); a zero NO filter (Sievers Instruments) was attached to the inspiratory input to avoid environmental contamination.

Pulmonary mechanics evaluation. After the ENO measurement, a mechanical evaluation was conducted. The tracheal pressure (Ptr) was measured with a 142PC05D differential pressure transducer (Honeywell, Freeport, IL) connected to a side tap in the tracheal cannula. Airflow (V) was obtained using a pneumotachograph (Fleisch, Richmond, VA) connected to the tracheal cannula and to a Honeywell 163PC01D36 differential pressure transducer. Lung volume (V) changes were determined by digital integration of the airflow signal. Nine to ten respiratory cycles were averaged to obtain each data point. The Ptr, V′, and V signals were collected before and after the SAL or OVA challenge and stored on a microcomputer (30, 35, 36, 44). The baseline measurements of Ptr and V′ were performed after the animal was stabilized on the ventilator. Subsequently, 2-min challenges with an aerosol of either ovalbumin (30 mg/ml for the OVA and OVA-RHO groups) or normal saline (for the SAL and SAL-RHO groups) were delivered into the inspiratory circuit through the air inlet of the ventilator. Measurements of Ptr and V′ were taken 1 and 3 min after the start of the first challenge. Respiratory system elastance (ERS) and resistance (Rrs) values were obtained using the equation of motion of the respiratory system: \( \text{Ptr}(t) = \text{ERS} \cdot \text{V}(t) + \text{Rrs} \cdot \text{V′}(t) \), where t is time. Immediately after the end of the mechanical evaluation, a positive end-expiratory pressure of 5 cmH2O was applied to the respiratory system, and the airways were occluded at the end of expiration to maintain the insufflation of the lungs. The GP were then exsanguinated via the abdominal aorta, the anterior chest wall was removed, and the lungs were removed en bloc for morphometric studies and histological analysis.

Morphometric studies. The removed lungs were fixed with buffered 4% paraformaldehyde for 24 h and then transferred to 70% ethanol. Random sections representing peripheral areas of the lungs were processed for paraffin embedding. Histological sections 5 μm thick were obtained. For the immunohistological experiments, the sections were deparaffinized and washed three times for 10 min each with H2O2 10V 3% to inhibit endogenous peroxidase activity. Morphometric analysis was performed with a light microscope with an integrating eyepiece (with a reticle with 100 points and 50 lines) using a point-counting technique. As the reticle should be placed adjacent to the airway wall, we selected transversely sectioned noncartilaginous airways for analysis. Morphometric analysis of the area of airway wall inflammation was made counting the number of eosinophils or positive cells between the basal membrane of the airway epithelium and the airway smooth muscle. Data did not include the epithelium.

Quantification of eosinophils. For the eosinophil counts, the lungs were stained with Luna’s eosinophil granule stain (48). Three airways were randomly selected from each lung section and examined at a
magnification of ×1,000. The number of eosinophils was determined as the number of positive cells in each field divided by the number contacting the airway wall area (10^4 μm^2).

**Quantification of collagen and elastic fibers.** The lungs were also stained with Picrosirius, a method for collagen identification, and Weigert’s Resorcin-Fuchs in, a method for visualizing elastic fibers. Three different airways were randomly selected from each lung to quantify collagen and elastic fiber contents. Quantification was performed by the same method described above. The lung sections were examined at ×1,000 magnification, and the volume proportion of collagen and elastic fibers was determined by dividing the number of points contacting collagen or elastic fibers by the total number of points contacting the tissue in the airway area (between basal membrane of the epithelium and the airway smooth muscle). The results were expressed as percentages.

**Evaluation of cytokine-positive cells.** For the cytokine evaluations, antigen retrieval was performed with citrate solution for 30 min. Sections were incubated with anti-IL-2, anti-IL-4, anti-IL-5, and anti-IL-13 (all from Santa Cruz Biotechnology, Santa Cruz, CA) and left overnight at 48°C diluted in BSA in the proportions 1:200 (IL-5 and IL-13), 1:400 (IL-2), or 1:500 (IL-4). An ABC Vectastain Kit (Vector Laboratories, Burlingame, CA) was used as the secondary antibody, and 3,3′-diaminobenzidine (DAB) (Dako Cytomation, Carpinteria, CA) was used as a chromogen. The sections were counterstained with Harris hematoxylin (Merck). Three airways were analyzed per lung at a magnification of ×1,000, as described above. The positive cells were expressed in cells/unit area (10^5 μm^2).

**Evaluation of iNOS.** To detect inducible NO synthase (iNOS) activity, immunohistochemistry was performed using a labeled streptavidin–biotin (LSAB) method to visualize iNOS antibody. The antigen retrieval was performed at high temperature in a citrate buffer at pH 6.0. After this treatment, the sections were washed in PBS. Sections were incubated with primary iNOS antibody diluted 1:400 (LabVision; NeoMarkers, Fremont, CA) and incubated overnight. The sections were then washed in PBS and incubated with rabbit IgG using the ABC Elite Kit (PK-6101; Vector Laboratories). Next, the sections were again washed, and 3,3′-DAB (Dako Cytomation) was used as a chromogen. The sections were washed in flowing water and counterstained with Harris hematoxylin (Merck). Three airways were analyzed per lung at a magnification of ×1,000, as described above. The number of positive cells was expressed as cells/unit area (10^5 μm^2).

**Evaluation of 8-isoprostane-PGF2α.** Immunohistochemical staining was performed using an antibody to anti-8-epi-prostaglandin F (PGF)2α (Oxford Biomedical Research, Rochester Hills, MI) at a 1:500 dilution. Antigen retrieval was performed with trypsin for 20 min. Subsequently, three washes in PBS were performed for 3 min each. Sections were incubated with anti-8-epi-PGF2α (1:500) diluted in BSA overnight. After washes in PBS, the ABC Vectastain kit (Vector Laboratories) was used to provide a secondary antibody, and 3,3′-DAB (Dako Cytomation) was used as a chromagen. The sections were counterstained with Harris hematoxylin (Merck). Three airways were analyzed per lung at a magnification of ×1,000, as described above. The number of positive cells was expressed as cells/unit area (10^5 μm^2).

**Evaluation of actin.** The immunohistochemistry to detect actin utilized the LSAB method for the detection of human smooth-muscle actin markers (Dako). Antibody retrieval for the smooth-muscle actin marker was performed at high temperature in a citrate solution at pH 6.0 for 30 min. After this treatment, the sections, still immersed in the same solution, were cooled to room temperature for 20 min and washed in PBS three times. Before the incubation with the primary antibody, protein blocking with 2% skim milk was performed for 10 min. The sections were then washed again in PBS and incubated with the LSAB Plus-HRP kit (Dako). The chromogen used was again 3,3′-DAB (Dako). Finally, the sections were washed in water and counterstained with Harris hematoxylin (Merck). Antigen retrieval was performed by applying the same point-counting technique described above. The proportion of actin in the area of the airway wall was obtained as the ratio between the numbers of coinciding points on actin and unstained tissue. The sections were examined at a magnification of ×1,000, and the results were expressed as percentages.

**Evaluation of TIMP-1.** The immunohistochemistry used for the tissue inhibitor of metalloproteinase (TIMP)-1 assay utilized the peroxidase enzyme. Antigen retrieval was performed at a high temperature in a citrate buffer at pH 6.0 for 1 min. After this treatment, the sections were washed in flowing water, distilled water, and PBS. Subsequently, endogenous peroxidase blocking was performed with methanol V/V and H2O2 10V 3% for 10 min and then with H2O2 10V 3% only three times for 5 min each. The sections were then washed again with flowing water, distilled water, and PBS. After the blocking, a TIMP-1 monoclonal antibody (Lab Vision) diluted 1:50 in BSA was applied to the sections and incubated from 2°C to 8°C overnight for at least 12 h. The sections were then washed in PBS and incubated with the Novolink Polymer Kit (Novocastra, Newcastle, UK). After this step, the sections were washed in PBS and 3,3′-DAB (Sigma Chemical) was used as a chromogen. Finally, the sections were washed with water and counterstained with Harris hematoxylin (Merck). Three airways were analyzed per lung at a magnification of ×1,000, as described above. The number of positive cells was expressed as cells/unit area (10^5 μm^2).

**Evaluation of MMP-9, TGF-β, NF-κB, and IFN-γ.** The immunohistochemistry to detect cells expressing matrix metalloproteinase (MMP)-9, transforming growth factor (TGF)-β, NF-κB, and IFN-γ followed procedures similar to those described above using the LSAB method. Antigen retrieval was achieved at a high temperature. After this treatment, the sections were washed in flowing water, deionized water, and PBS. After blocking, primary monoclonal antibodies diluted in BSA were applied over the sections in the following ratios and incubated overnight: MMP-9, 1:500 (Lab Vision); TGF-β, 1:1,500 (Santa Cruz Biotechnology); NF-κB, 1:50 (Santa Cruz Biotechnology); and IFN-γ, 1:50 (Santa Cruz Biotechnology). The sections were then washed in PBS and incubated. After this step, the sections were washed in PBS and visualized with the 3,3′-DAB chromogen (Dako Cytomation). Finally, the sections were washed in flowing water and counterstained with Harris hematoxylin (Merck). Three airways were analyzed per lung at a magnification of ×1,000, as described above. The number of positive cells was expressed as cells/unit area (10^5 μm^2).

**Passive cutaneous anaphylaxis.** For the titration of the IgG1 and IgE antibodies, we used the technique of Ovary (1964) as modified by Mota and Perini (28). Three GP from each group were anesthetized with pentobarbital sodium (50 mg/kg ip), and 5 ml of blood was drawn by cardiac puncture. The blood was centrifuged at 1,000 rpm for 20 min at a temperature of 4°C. For the IgG1 titration, a portion of the sample was heated in a water bath at 56°C for 1 h to inactivate IgE antibodies. The backs of the GP were trichotomized, taking care not to irritate the skin. Aliquots of 0.1 ml of each concentration of serum (from 1:5 to 1:2,560) were injected into the dorsal subcutaneous tissues of the GP. After 24 h for IgG1 and 10 days for IgE, a solution containing 1 mg of ovalbumin, 1 mg of Evans blue, and 0.25% saline was injected into the bloodstream. After 30 min, the animals were killed, their skin removed and inverted, and the diameters of the reactions were analyzed, with reactions larger than 5 mm in diameter considered to be positive. The titers were determined as the highest dilution of serum that induced a passive cutaneous anaphylactic reaction.

**Statistical analysis.** All data are reported as the means ± SE. The statistical significance of differences between groups was determined by ANOVA followed by the Holm-Sidak method for multiple com-
We also obtained the Pearson correlation coefficient (\(R\)) to assess the associations of the \(R_{rs}\) and \(E_{rs}\) scores with the markers for remodeling, inflammatory cells, and oxidative stress. All statistical analysis was performed using SigmaStat software (Systat Software, San Diego, CA). Differences were considered significant when \(P < 0.05\).

RESULTS

Inhalation time. There were no differences in the inhalation times among the groups studied until the fourth inhalation, and all animals reached 15 min of inhalation. None of the normal saline groups (SAL and SAL-RHO groups) presented respiratory distress during the seven inhalations. From the fifth to seventh inhalation, sensitized and untreated animals (the OVA group) presented lower inhalation times compared with the group that was sensitized and treated with Y-27632 (OVA-RHO group) (8.87 \(\pm\) 2.59 min and 12.52 \(\pm\) 2.9 min, respectively; \(P < 0.05\)).

ENO. Figure 2 presents the levels of ENO measured at 72 h after the last inhalation with saline or OVA challenge. The concentrations of ENO were higher in the OVA group (27.9 \(\pm\) 1.92 ppb) than in the SAL (15.9 \(\pm\) 0.69 ppb) and SAL-RHO (14.5 \(\pm\) 0.88 ppb) groups (\(P < 0.001\)). The treatment with Y-27632 reduced the ENO of the OVA-RHO group (20.2 \(\pm\) 2.55 ppb) compared with the OVA group (\(P < 0.05\)).

Pulmonary mechanical evaluation. There were no differences in the baseline values of the respiratory system resistance and elastance among the experimental groups (see Table 1). The percentage of maximal increase of \(R_{rs}\) is illustrated in Fig. 3A. There was a significant increase of %\(R_{rs}\) in the OVA group (141.86 \(\pm\) 6.6%) compared with the controls (SAL group: 7.99 \(\pm\) 1.66%; SAL-RHO group: 6.2 \(\pm\) 2.74%). The treatment of sensitized animals with the Rho-kinase inhibitor attenuated this response (OVA-RHO group: 7.68 \(\pm\) 2.69%; \(P < 0.001\)).

The percentage of maximal increase of \(E_{rs}\) is shown in Fig. 3B. There was also a significant increase of %\(E_{rs}\) in the OVA group (10.88 \(\pm\) 2.12%) compared with the control groups (SAL: 3.20 \(\pm\) 0.19%; SAL-RHO: 2.39 \(\pm\) 0.13%). The inhibition of Rho-kinase reduced this response compared with the OVA group (OVA-RHO group: 2.28 \(\pm\) 0.21%; \(P < 0.001\)).

Table 1. Baseline values of the \(R_{rs}\) and \(E_{rs}\) among the experimental groups

<table>
<thead>
<tr>
<th>Group</th>
<th>(R_{rs}), cmH(_2)O (\cdot) ml(^{-1}) (\cdot) s (^{-1})</th>
<th>(E_{rs}), cmH(_2)O/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAL</td>
<td>0.23 (\pm) 0.01</td>
<td>2.64 (\pm) 0.16</td>
</tr>
<tr>
<td>OVA</td>
<td>0.20 (\pm) 0.02</td>
<td>2.50 (\pm) 0.22</td>
</tr>
<tr>
<td>SAL-RHO</td>
<td>0.11 (\pm) 0.01</td>
<td>2.23 (\pm) 0.10</td>
</tr>
<tr>
<td>OVA-RHO</td>
<td>0.25 (\pm) 0.05</td>
<td>1.82 (\pm) 0.22</td>
</tr>
</tbody>
</table>

Values are means \(\pm\) SE. SAL, saline group; OVA, ovalbumin group; RHO, Rho-kinase group; \(R_{rs}\), respiratory system resistance; \(E_{rs}\), respiratory system elastance.

Fig. 2. Vertical bar graph representing the means \(\pm\) SE of the ENO concentrations of the anesthetized guinea pigs. The ENO was collected 72 h after the 7th inhalation (before the challenge) with saline or OVA solutions in the 4 experimental groups. *\(P < 0.05\) compared with the other groups; **\(P < 0.05\) compared with OVA group.

Fig. 3. Vertical bar graph showing the means \(\pm\) SE of the maximal percentage increases in respiratory system resistance (\(R_{rs}\) \(A\)) and elastance (\(E_{rs}\) \(B\)) obtained after airway challenge with ovalbumin (30 mg/ml) or normal saline in anesthetized guinea pigs. *\(P < 0.001\) compared with the SAL, SAL-RHO, and OVA-RHO groups; **\(P < 0.001\) compared with the OVA group.
Y-27632 presented lower elastic fiber contents than the sensitized and untreated animals (OVA-group; \( P < 0.05 \)).

There was an increase in the collagen contents in the airways of the ovalbumin-exposed GP (OVA: 22.57 ± 1.24%; OVA-RHO: 14.09 ± 2.65%) compared with the saline-exposed ones (SAL: 13.64 ± 1.59%; SAL-RHO: 14.45 ± 2.09%). The treatment with Y-27632 also attenuated the collagen fiber content in the ovalbumin-exposed animals (\( P < 0.05 \)). These data are presented in Fig. 4B.

Figure 5 shows the values of eosinophil density in the airways of the four experimental groups. We observed an increase in eosinophil density in the ovalbumin-exposed GP (OVA: 27.42 ± 4.95 cells cells/10^4 \( \mu m^2 \)) compared with the controls (SAL: 6.67 ± 1.38 cells/10^4 \( \mu m^2 \); SAL-RHO: 4.57 ± 0.44 cells/10^4 \( \mu m^2 \); \( P < 0.001 \)). The treatment with the Rho-kinase inhibitor reduced the numbers of these cells in the animals exposed to ovalbumin challenge (OVA-RHO: 13.26 ± 1.39 cells/10^4 \( \mu m^2 \); \( P < 0.05 \)). The values of eosinophil density were also verified for the OVA-wRHO group, and the difference to OVA group was retained (\( P < 0.05 \)).

Figure 6A presents the numbers of IL-2-positive cells for all experimental groups. There was increase in IL-2-positive cells in the airways of the untreated ovalbumin-sensitized animals (the OVA group: 33.07 ± 0.72 cells/10^4 \( \mu m^2 \)) compared with the groups exposed to inhalation with saline solution (SAL group: 2.86 ± 0.72 cells/10^4 \( \mu m^2 \); SAL-RHO group: 6.70 ± 1.12 cells/10^4 \( \mu m^2 \); \( P < 0.001 \)). The number of IL-2-positive cells in the OVA-exposed group that was also treated with Y-27632 was reduced (OVA-RHO group: 11.08 ± 0.87 cells/10^4 \( \mu m^2 \); \( P < 0.001 \)).

We also observed (Fig. 6B) an increase in the number of IL-4-positive cells in untreated animals exposed to ovalbumin challenges (OVA group: 14.44 ± 1.16 cells/10^4 \( \mu m^2 \)) compared with the animals of the control groups (SAL: 3.19 ± 0.90 cells/10^4 \( \mu m^2 \); SAL-RHO: 2.59 ± 0.74 cells/10^4 \( \mu m^2 \)) and the treated group (OVA-RHO: 8.53 ± 1.13 cells/10^4 \( \mu m^2 \)), for which we observed an attenuation of the IL-4-positive cell

**Morphometric analysis.** The volume proportion of elastic fibers was illustrated in Fig. 4A. The elastic fiber contents were higher in the OVA-exposed animal groups (OVA: 8.01 ± 0.63%; and OVA-RHO: 4.09 ± 0.45%) compared with the saline-exposed GP (SAL group: 1.38 ± 0.63%; SAL-RHO group: 1.45 ± 0.47%; \( P < 0.001 \)). The animals treated with

---

**Fig. 4.** Vertical bar graph showing the means ± SE of the elastic fiber (A) and collagen (B) contents for the 4 experimental groups. The results are expressed as percentages. *\( P < 0.05 \) compared with the SAL and SAL-RHO groups; **\( P < 0.05 \) compared with the OVA group; and #\( P < 0.05 \) compared with all other groups.

**Fig. 5.** Vertical bar graph showing the means ± SE of the eosinophil densities in the lungs of the animals exposed to inhalations with ovalbumin or normal saline and treated with Rho-kinase inhibitor or vehicle. *\( P < 0.05 \) compared with the SAL, SAL-RHO, and OVA-RHO groups; **\( P < 0.001 \) compared with OVA group.
counts ($P < 0.001$). Despite this attenuation of the number of IL-4-positive cells in the treated animals, there was a difference in the values of this group in relation to the control group ($P < 0.001$).

Figure 6C shows the number of IL-5-positive cells in the airways of the GP of the four experimental groups. We observed an increase in the number of IL-5-positive cells in the airways of the ovalbumin-sensitized animals (OVA group: $19.86 \pm 2.49$ cells/$10^4 \mu m^2$ and OVA-RHO group: $14.42 \pm 1.71$ cells/$10^4 \mu m^2$) compared with the controls (SAL group: $5.17 \pm 0.50$ cells/$10^4 \mu m^2$; SAL-RHO group: $5.68 \pm 0.25$ cells/$10^4 \mu m^2$; $P < 0.001$). We observed reduced numbers of IL-5-positive cells in the airways of the GP sensitized to ovalbumin and treated with Y-27632 in relation to the OVA group animals ($P < 0.05$), although there was a significant difference between the treated animals and the control group ($P < 0.001$).

The numbers of IL-13-positive cells are illustrated in Fig. 6D. The group of GP exposed to ovalbumin presented a higher number of IL-13-positive cells (OVA: $13.39 \pm 1.85$ cells/$10^4 \mu m^2$) than the groups exposed to saline (SAL: $8.40 \pm 1.28$ cells/$10^4 \mu m^2$; SAL-RHO: $6.22 \pm 1.34$ cells/$10^4 \mu m^2$; $P < 0.05$). Ovalbumin-exposed GP that received treatment with the Rho-kinase inhibitor presented a reduced number of IL-13-positive cells (OVA-RHO group: $8.71 \pm 0.72$ cells/$10^4 \mu m^2$) compared with the OVA group ($P < 0.05$).

We also observed (Fig. 6E) an increase in the number of cells positive for IFN-γ in the untreated animals exposed to ovalbumin challenges (OVA group: $32.14 \pm 1.5$ cells/$10^4 \mu m^2$) compared with the control groups (SAL: $16.31 \pm 1.46$ cells/$10^4 \mu m^2$; RHO-SAL: $16.53 \pm 1.94$ cells/$10^4 \mu m^2$) and the group treated with the Rho-kinase inhibitor (OVA-RHO: $19.58 \pm 2.09$ cells/$10^4 \mu m^2$), for which we observed an attenuation of IFN-γ-positive cells ($P < 0.001$).

The measurements of the iNOS-positive cells are presented in Fig. 7A. The number of iNOS-positive cells was significantly higher in the untreated ovalbumin-exposed animals (OVA group: $14.69 \pm 1.09$ cells/$10^4 \mu m^2$) compared with the saline-exposed animals (SAL group: $9.65 \pm 1.37$ cells/$10^4 \mu m^2$; SAL-RHO group: $9.05 \pm 0.7$ cells/$10^4 \mu m^2$; $P < 0.05$) and the Y-27632-treated animals exposed to ovalbumin (OVA-RHO group: $10.37 \pm 0.68$ cells/$10^4 \mu m^2$; $P < 0.05$).

The volume proportions of 8-iso-PGF2α in the airways of the GP are illustrated in Fig. 7B. We observed increased 8-iso-PGF2α contents in the airways of the OVA-exposed animals groups (OVA: $25.93 \pm 1.62\%$) compared with the saline-exposed guinea pigs (SAL group: $16.55 \pm 2.33\%$; SAL-RHO group: $15.73 \pm 1.89\%$; $P < 0.05$). The animals

Fig. 6. Vertical bar graph showing the means ± SE of the cytokine-positive cells in the airways of the animals; IL-2 (A), IL-4 (B), IL-5 (C), IL-13 (D), and IFN-γ (E). The untreated ovalbumin-exposed animals had greater numbers of all types of interleukin-positive cells than those in the other groups. Treatment with the Rho-kinase inhibitor presented a reduced number of IL-13-positive cells in the airway wall areas. *$P < 0.05$ compared with the other groups; **$P < 0.001$ compared with OVA group; and # $P < 0.05$ compared with the OVA group.
treated with Y-27632 presented lower contents of 8-iso-PGF2α (OVA-RHO group: 15.58 ± 2.97%) compared with both the sensitized and untreated animals.

The numbers of NF-κB-positive cells are presented in Fig. 7C. The numbers of NF-κB-positive cells were significantly higher in the untreated animals exposed to ovalbumin (OVA group: 15.37 ± 1.72 cells/10⁴ µm²) than in the groups exposed to saline (SAL: 5.12 ± 0.69 cells/10⁴ µm²; SAL-RHO: 5.05 ± 0.9 cells/10⁴ µm²; P < 0.001) and the ovalbumin-exposed animals treated with Y-27632 (OVA-RHO group: 6.58 ± 0.92; P < 0.001).

There was also statistically significant differences of smooth-muscle-specific actin present in the airway walls between groups. We observed increased smooth-muscle-specific actin contents in the airways of the ovalbumin-exposed animals groups (OVA: 25.75 ± 1.31%) compared with the saline-exposed GP (SAL group: 9.84 ± 1%; SAL-RHO group: 9.94 ± 0.9%; P < 0.001), and with the sensitized and treated animals (OVA-RHO group: 12.16 ± 0.69%; P < 0.001).

The numbers of MMP-9-positive cells are shown in Fig. 8A. There was a significant increase in the number of MMP-9-positive cells in the OVA group (24.01 ± 0.90 cells/10⁴ µm²) compared with the controls (SAL group: 14.09 ± 1.25 cells/10⁴ µm²; SAL-RHO group: 12.89 ± 1.7 cells/10⁴ µm²; P < 0.001). The treatment of the sensitized animals with the Rho-kinase inhibitor attenuated this response (OVA-RHO group: 13.20 ± 1.96; P < 0.001).

Fig. 8B presents the numbers of TIMP-1-positive cells for all experimental groups. The number of cells positive for TIMP-1 also increased in the airways of the untreated animals exposed to ovalbumin (OVA group: 15.52 ± 2.63 cells/10⁴ µm²) compared with the groups exposed to inhaled saline (SAL group: 5.79 ± 1.01 cells/10⁴ µm²; SAL-RHO group: 4.71 ± 0.76 cells/10⁴ µm²; P < 0.001). The number of TIMP-1-positive cells in the group exposed to OVA but treated with Y-27632 was reduced (OVA-RHO group: 9.03 ± 0.53 cells/10⁴ µm²; P < 0.05).

The number of TGF-β-positive cells is shown in Fig. 8C. The group of GP exposed to ovalbumin showed a higher number of cells positive for TGF-β (OVA group: 10.8 ± 0.54 cells/10⁴ µm²) than the groups exposed to saline (SAL: 6.95 ±

---

**Fig. 7.** Vertical bar graph showing the means ± SE of the numbers of cells positive for the expression of inducible nitric oxide synthase (iNOS) (A), 8-isoprostane-prostaglandin F2α (B), and NF-κB (C) present in the airways of guinea pigs from all the experimental groups. *P < 0.05 compared with the SAL, SAL-RHO, and OVA-RHO groups; **P < 0.001 compared with the OVA group; and #P < 0.05 compared with the OVA group.

**Fig. 8.** Vertical bar graph showing the means ± SE of the numbers of matrix metalloproteinase (MMP)-9 (A), tissue inhibitor of metalloproteinase (TIMP)-1 (B), and TGF-β-positive cells (C) in the airways of guinea pigs exposed to 7 inhalations with saline or ovalbumin and repeatedly treated with Y-27632 or vehicle. The results are expressed as percentages. *P < 0.05 compared with the other groups; **P < 0.001 compared with the OVA group; and #P < 0.05 compared with the OVA group.
0.73 cells/10^4 μm^2; SAL-RHO: 6.14 ± 1.21 cells/10^4 μm^2; *P < 0.05). The GP exposed to ovalbumin and treated with the Rho-kinase inhibitor showed a decreased number of TGF-β-positive cells (OVA-RHO group: 8.07 ± 0.67 cells/10^4 μm^2) compared with the OVA group (*P < 0.05).

Table 2 presents the correlations of Rs and Es with the measures for inflammatory cells, remodeling markers, and oxidative stress markers. We observed significant correlations among all the parameters evaluated. In relation to the passive cutaneous anaphylaxis (PCA), there were no detectable IgG1 antibodies in the SAL and SAL-RHO groups. The PCA showed an increase in specific anaphylactic IgG1 antibodies in GP exposed to ovalbumin (OVA group; maximum titration, 1:640). This response was reduced in the animals treated with Y-27632 (OVA-RHO group; maximum titration, 1:160).

Figure 9 shows representative photomicrographs of GP airways stained for cells expressing IL-2, IL-4, IL-5, and IL-13. The untreated GP subjected to ovalbumin challenge (OVA group) presented prominent increases in the numbers of all cytokine-positive cells (Fig. 9, B, F, J, and N) compared with the unsensitized animals (SAL group: Fig. 9, A, E, I, and M; SAL-RHO group: Fig. 9, C, G, K, and O) and the animals in the OVA-RHO group (Fig. 9, D, H, L, and P) receiving treatment with the Rho-kinase inhibitor.

Representative photomicrographs of the airways of the animals stained with Picrosirius for collagen content, Weigert Resorcin-Fuchsin for elastic fiber content, and immunohistochemistry for the volume proportions of actin and 8-iso-PGF2α are shown in Fig. 10. Except for actin content, for which no difference was found among the groups, all the other fiber contents were elevated in the untreated ovalbumin-exposed animals (OVA group; Fig. 10, B, F, J, and N) compared with the saline-exposed animals (SAL group; Fig. 10, A, E, I, and M; SAL-RHO group; Fig. 10, C, G, K, and O). The treatment of the GP exposed to ovalbumin with the Rho-kinase inhibitor reduced the contents of collagen fibers (Fig. 10D), elastic fibers (Fig. 10H), and 8-iso-PGF2α (Fig. 10L).

Figure 11 presents photomicrographs of airway walls from GP in the four experimental groups subjected to Luna staining for the detection of eosinophil density and immunohistochemical staining for iNOS, NF-κB, and IFN-γ detection. The animals exposed to ovalbumin (the OVA group) presented intense eosinophilic infiltration (Fig. 11B) and increased numbers of iNOS- (Fig. 11F), NF-κB- (Fig. 11J), and IFN-γ- (Fig. 11N) positive cells compared with the saline-exposed animals (SAL group; Fig. 11, A, E, I, and N; SAL-RHO group; Fig. 11, C, G, K, and O). Treatment with Y-27632 decreased the degree of eosinophilic infiltration (Fig. 11D) and the numbers of iNOS- (Fig. 11H), NF-κB- (Fig. 11L), and IFN-γ- (Fig. 11P) positive cells in the ovalbumin-exposed GP.

Representative photomicrographs of immunohistochemical staining for MMP-9, TIMP-1, and TGF-β in the airways of the four animal groups are shown in Fig. 12. There was an increase in the numbers of MMP-9-, TIMP-1-, and TGF-β-positive cells in the groups of untreated ovalbumin-exposed animals (OVA group; Fig. 12, B, F, and J, respectively) compared with the saline-exposed animals (SAL group; Fig. 12, A, E, and I; and SAL-RHO group; Fig. 12, C, G, and K). Treatment of the GP exposed to ovalbumin with Y-27632 reduced the numbers of MMP-9- (Fig. 12D), TIMP-1 (Fig. 12H), and TGF-β- (Fig. 12L) positive cells. Note that, although the microscopic analyses were performed at a magnification of ×1,000, we chose to present photomicrographs at lower magnifications to better highlight the differences among the groups.

### DISCUSSION

In the present study, we evaluated the role of Y-27632, a Rho-kinase inhibitor, on oxidative stress, respiratory system mechanics, inflammation, and extracellular matrix remodeling in the airways of GP with chronic allergic airway inflammation. The results showed that repeated Rho-kinase inhibition reduced the airway mechanical responses to antigenic challenge, with correlated reductions in Easo nitrogen oxides, the numbers of IL-2-, IL-4-, IL-5- and IL-13-positive cells, and extracellular matrix remodeling in the airway wall. Additionally, there was a significant reduction in the activation of the oxidative stress pathway, which was also correlated with the attenuation of the maximum mechanical responses after antigen challenge.

We previously studied this model of chronic allergic pulmonary inflammation in GP, and the present results confirm our previous data, demonstrating that the ovalbumin-sensitized animals required shorter lengths of time in contact with the antigen during the challenges (23, 31, 44). In addition, these previous studies confirmed the presence of airway hyperresponsiveness (23, 30, 31, 35), inflammation (31, 32, 35), and remodeling (30, 32, 35) in the sensitized GP, constituting an
interesting model for the study of possible therapeutic strategies for asthma.

The treatment with the Rho-kinase inhibitor was started on the fifth inhalation to avoid possible interference with the sensitization process. We also previously demonstrated that, at this time, the GP were already sensitized and showed an increase in the level of IgG1-specific anaphylactic antibodies detected using the PCA technique (44). This elevation of IgG1-specific antibodies in ovalbumin-exposed groups was also demonstrated in the present study.

Acute responses to antigen exposure were evaluated by the time that guinea pigs were able to be in contact with the ovalbumin aerosol (inhalation time). In this context, treatment with Rho-kinase inhibitor attenuated this response in the sensitized animals. We reasoned that an acute response to antigen challenge may be related to several mechanisms including:
smooth-muscle responses that were likely modified by Y-27632 treatment. The repeated treatment with Y-27632 caused a significant decrease in the level of NO exhaled from ovalbumin-sensitized GP. Note that this may have occurred due to the acute effects of Y-27632, used 1 h before ENO measurement.

The ENO is a well-established, noninvasive biomarker of airway inflammation that can be used for the assessment of asthma severity, as elevated ENO levels are associated with airway inflammation that can be used for the assessment of Y-27632, used 1 h before ENO measurement. Note that this may have occurred due to the acute effects of Y-27632, used 1 h before ENO measurement.

Fig. 11. Representative photomicrographs of guinea pig airways stained with Luna (A–D, ×400) and immunohistochemistry results for iNOS (E–H, ×400), NF-κB (I–L, ×400), and IFN-γ (M–P, ×400). All experimental groups are represented: SAL (A, E, I, and M), OVA (B, F, J, and N), SAL-RHO (C, G, K, and O), and OVA-RHO (D, H, L, and P).

One of the most important factors that must be considered in the development of new therapies for asthma (5).

Several studies have reported the beneficial effects of Rho-kinase inhibition on airway hyperresponsiveness in sensitized animals (7, 9, 15, 40, 38, 43, 51). The influence of Rho-kinase on airway hyperresponsiveness appears to be, at least in part, related to agonist-mediated Ca^{2+} sensitization. The mechanisms responsible for this Ca^{2+} sensitization have not been fully elucidated, but recent studies suggest that Rho-kinase is a key protein involved in the contraction of smooth muscles; therefore, Rho-kinase presents a potential therapeutic target for asthma therapy (5, 13, 21, 37).

The activated Rho-kinase promotes the phosphorylation of the myosin light chain and contributes to an increased level of muscular contraction (5, 40).

The effects of acute inhibition of Rho-kinase in sensitized animals have been analyzed in several studies (6, 11, 12, 14, 16, 37, 49, 52). Schaafsma et al. (38) showed that inhalation of Y-27632 at 30 min before and 8 h after allergen challenge in sensitized GP effectively prevents the development of airway hyperresponsiveness, after both the early and late airway reactions.

It has also been reported that Y-27632 reduces cholinergic nerve-mediated contractions in tracheal preparations of GP and mice in a dose-dependent manner (6). However, as with β_{2}-adrenoceptor bronchodilators, Y-27632 increases neurotransmitter release from airway cholinergic nerves. The mechanism responsible for this neurotransmitter release increase remains unclear (6, 52).

The increases in airway resistance induced by methacholine in allergic mice are also reduced with intranasal administration of Y-27632 at least 8 h after instillation of the Rho-kinase inhibitor (16). Witzenrath et al. (49) verified that the use of Y-27632 attenuated the methacholine-provoked airway response in sensitized lungs.
In addition to reducing airway hyperresponsiveness by promoting smooth-muscle contractility, Rho-kinase appears to mediate airway hyperresponsiveness induced by lysophosphatic acid (14, 15). The bronchodilating action of Y-27632 was also studied as an adjuvant for isofluorane, a volatile anesthetic traditionally used to treat status asthmaticus, with effects associated with both Ca\(^{2+}\)/H\(_{100}\) and Ca\(^{2+}\)/H\(_{100}\)-independent contraction in airway smooth muscles (12). Hanazaki et al. (11) reported that the isofluorane-induced relaxation of rat bronchial smooth muscle was significantly augmented by a subthreshold concentration of Y-27632. Assuming that this may have occurred due to the acute effect of the drug on the airways, once the inhibitor Y-27632 was used 1 h before collection of data of pulmonary mechanics, we chose to create one more experimental group (OVA-wfRHO) that had not received the last inhalation. We verified that there was no difference in results of the maximal responses of E\(_{\text{rs}}\) and R\(_{\text{rs}}\) after ovalbumin challenge between the OVA-wfRHO and OVA-Rho groups. These data confirmed that the initial obtained results were really related to the repeated use of Y-27632 during the experimental protocol. Also, it is important to emphasize that we are not aware of any previous studies analyzing the effects of repeated Rho-kinase inhibition. We believe that repeated inhibition complements these studies in a fundamental way to demonstrate the potential importance of the Rho-kinase inhibitors in the treatment of asthma. Moreover, the experimental model used herein presents a chronic allergic inflammation response.

As in previous studies (31, 32, 44), we observed an increase in the number of eosinophils in the airways of the sensitized GP. We also noted that the Rho-kinase inhibitor significantly attenuated this response in the sensitized animals. Furthermore, we observed that Rho-kinase inhibition attenuated the numbers of IL-2, IL-4, IL-5, and IL-13-positive cells around the airway walls. Note that it is possible that the effects of Y-27632 on eosinophilia and cytokine expression can be partially attributed to an acute Rho-kinase inhibition, once the Rho-kinase inhibitor was used 1 h before collection of lungs for morphometric analysis. As above described, we compared the evaluation of eosinophilic infiltration in the new group OVA-wfRHO, and we did not find any differences between OVA-RHO and OVA-wfRHO animals. These results suggest that the repeated Rho-kinase inhibition modulates upstream signaling events involved in eosinophil recruitment into the airways during an allergic inflammatory response.

Several studies have suggested that the RhoA/ROCK system plays a role in eosinophil recruitment and Th-1 and Th-2 cytokine secretion (1, 2, 16). In this regard, Henry et al. (16) demonstrated that pretreatment with Y-27632 reduced the number of eosinophils recovered from the bronchoalveolar lavage (BAL) fluid of OVA-sensitized mice (16).

Taki et al. (43) demonstrated that another Rho-kinase inhibitor, fasudil, reduced the numbers of eosinophils in BAL fluid, airways, and blood vessels. This Rho-kinase inhibitor also diminished the augmented levels of IL-5, IL-13, and eotaxin in BAL fluid (43). Aihara et al. (2) showed that Y-27632 sup-
pressed the release of Th-1 cytokines and partially suppressed the release of Th-2 cytokines in healthy persons but reduced the release of IL-2 and IL-5 in asthmatic patients and weakly reduced the release of IL-4 and IFN-γ. In the present study, Rho-kinase inhibition was associated with significant reductions in levels of these interleukins and IFN-γ in animals sensitized to ovalbumin, indicating that there is indeed an association between the Rho/Rho-kinase pathway and the release of these mediators.

In this study, we also demonstrated attenuations of the number of cells positive for iNOS and the content of 8-iso-PGF2α in the area of the airway walls of sensitized animals by Rho-kinase inhibition with Y-27632. Our results are in agreement with those of McGown et al. (25), who investigated whether the Rho-kinase inhibitor fasudil protected against LPS-induced vascular leakage and leukocyte adhesion via iNOS pathways. The authors demonstrated that fasudil decreased LPS-induced upregulation of iNOS, reducing microvascular inflammation.

In addition, it is well known that iNOS activation may contribute to peroxynitrite formation, which is an oxidant agent formed by the interaction of NO and superoxide. Subsequently, isoprostane generation may result from lipid peroxidation induced by peroxynitrite formation (50). The inhibition of Rho-kinase caused a reduction in the number of iNOS-positive cells, which may have contributed to the attenuation of airway hyperresponsiveness, oxidative stress, and the consequent extracellular matrix remodeling. Further studies are necessary to clarify the exact mechanisms of action of Y-27632 on NO and oxidative stress.

Regarding the assessment of changes in extracellular matrix remodeling, there was a significant decrease in the contents of collagen and elastic fibers in the group of ovalbumin-exposed animals treated with the Rho-kinase inhibitor compared with the untreated groups. There is evidence that the experimental model of chronic pulmonary inflammation is associated with increased contents of collagen and elastic fibers in the airways and distal parenchyma (3, 24, 29, 42). However, we are not aware of previous experimental studies evaluating the role of Rho-kinase inhibition on the remodeling response.

This remodeling results from repair processes in response to persistent inflammation triggered by proinflammatory mediators, metalloproteinases, cytokines, and growth factors (46). In reducing the number of inflammatory cells, Rho-kinase inhibition by Y-27632 helps to prevent chronic inflammation and indirectly contributes to a reduction of remodeling, as evidenced by the lower contents of collagen and elastic fibers in the airway walls.

It is feasible that, in addition to indirect effects on fibrosis, Rho/ROCK signaling is directly involved in profibrotic processes, mediated by airway-resident cells. Schaafsm et al. (39) showed that human airway myocytes express both geranylgeranyl transferase 1 (GGT1) and farnesyltransferase (FT), and the inhibition of GGT1, but not FT, mirrored the suppressive effects of simvastatin on collagen I and fibronectin expression and collagen I secretion. The simvastatin and GGT1-286 both prevented TGF-β1-induced membrane association of RhoA, a downstream target of GGT1, suggesting that simvastatin and GGT1-286 inhibit synthesis and secretion of extracellular matrix proteins by human airway smooth muscle cells by suppressing GGT1-mediated posttranslational modification of signaling molecules such as RhoA.

Concerning these results, there are several recent studies suggesting the importance of Rho-kinase modulation on the remodeling process. Zhou et al. (53) analyzed the effects of fasudil on high-glucose-induced proliferation of cardiac fibroblasts and collagen production. The authors demonstrated that the activation of Rho-kinase is essential for the synthesis of collagen, which may be related to a combination of factors, including the inhibition of the JNK and TGF-β pathways, which are both involved in the fibrosis process.

Kondrikov et al. (20) investigated the role of Rho-kinase and reactive oxygen species (ROS) in the synthesis of collagen type I in human and mice lung fibroblasts subjected to hyperoxia in a model of oxygen toxicity. The authors concluded that oxygen toxicity induces ROS to separate the guanine nucleotide dissociation inhibitor (a regulator of Rho GTPase activity) from Rho, which leads to activation of the Rho-kinase pathway and contributes to increased collagen-I synthesis.

It was previously reported that iNOS inhibition reduces MMP-9, TIMP-1, and TGF-β. In addition to the reduction of iNOS, we also observed attenuations of the levels of MMP-9, TIMP-1, and TGF-β in the animals treated with the Rho-kinase inhibitor. These mediators act in the production of collagen and elastic fibers, thus contributing to extracellular matrix remodeling in the airways (47). The reduced level of iNOS-positive cells in the presence of Rho-kinase inhibition found in the present study and the reduced content of collagen and elastic fibers in the treated groups are probably due to the inhibition of this pathway. The reduced numbers of iNOS-positive cells when Rho-kinase is inhibited is in agreement with the results of other studies although the underlying mechanisms are unclear (25, 41).

There appears to be a relationship between these mediators and Rho-kinase. Jiang and George (18) demonstrated that the inhibition of Rho-kinase with Y-27632 prevented the reduction of NO induction by TGF-β2, avoiding inhibition of iNOS, suggesting that TGF-β2 inhibits iNOS expression via the Rho-kinase pathway in lung epithelial cells.

We also found that the level of another important inflammatory mediator, NF-κB, was reduced in the sensitized animals treated with the Rho-kinase inhibitor compared with the untreated animals. Similarly, Meyer-Schweizing er al. (26), when evaluating the role of Rho-kinase in inflammatory renal injury in mice, found that the inhibition of Rho-kinase was related to an attenuation of NF-κB signaling, resulting in protection against injury. These data suggest that the NF-κB signaling is also Rho-kinase dependent. The presence of airway smooth muscle tissue hypertrophy reinforces the idea that we used a model of chronic pulmonary inflammation and that the repeated use of Y-27632 attenuated this response.

The present study has several limitations. We used Rho-kinase inhibition by Y-27632 in an experimental model of chronic airway inflammation. We advise caution when extrapolating our findings directly to human physiology. However, our results support the importance of Rho-kinase in airway hyperresponsiveness, lung inflammatory responses, extracellular matrix remodeling, and oxidative stress pathway.

Additionally, it is important to note that the GP model is one of the best animal models for the study of asthma due to the similar lung anatomy of humans and GP and the presence of...
several characteristics of human asthma such as eosinophilic inflammatory and remodeling process (34). Additional studies are needed to elucidate the exact mechanisms responsible for these changes.

In conclusion, Rho-kinase pathway activation modulates hyperresponsiveness, inflammation, the extracellular matrix remodeling process, and oxidative stress activation. These results suggest that Rho-kinase inhibitors constitute potential pharmacological tools for the control of asthma.

ACKNOWLEDGMENTS

We thank Sandra de Moraes Ferneziani and Esmeralda Meristene for skillful technical assistance. We also thank Maria Luiza Vilela Oliva for execution of several of the experiments.

GRANTS

This work was supporfed by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS


REFERENCES


